πŸš€Clinical Research

Rising Incidence and Mortality of Endometrial Cancer Met with Immunotherapy and Molecular Subtype-Based Precision Treatment

LancetΒ·November 20, 2026AI Curation
Rising Incidence and Mortality of Endometrial Cancer Met with Immunotherapy and Molecular Subtype-Based Precision Treatment
✨AI Summary (Beta)Beta

Background

Endometrial cancer is the most common gynecological cancer in high-income countries and ranks sixth among all female cancers worldwide. Unlike most solid tumors, where mortality rates have declined due to advancements in modern medicine, endometrial cancer poses a serious public health threat as it is one of the few cancers where both incidence and mortality rates are increasing.

Approximately 75% of patients are diagnosed at an early stage, where cure is expected through surgical resection and adjuvant therapy if necessary. However, recent epidemiological studies indicate that high-risk subtypes, which progress more rapidly and exhibit greater treatment resistance than endometrioid carcinomas with a favorable prognosis, are increasing at a much steeper rate. A surge in high-risk patients is being driven by factors such as increasing obesity, an aging population, and hormonal imbalances.

In clinical practice, treatment decisions have traditionally relied on histological type and stage classification. However, even for the same cancer stage, recurrence risk and drug response vary drastically among patients, meaning that uniform cytotoxic chemotherapy alone has clear limitations in improving treatment outcomes. This has created an urgent need for new treatment strategies to improve the prognosis of patients diagnosed with recurrent or advanced disease.

Key Findings

This Lancet seminar report comprehensively highlighted the shift in treatment paradigms reflecting the molecular classification of The Cancer Genome Atlas (TCGA) alongside epidemiological changes in endometrial cancer. Endometrial cancer is clearly classified into four groups based on genetic characteristics: POLE-mutated, mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H), p53 abnormal (with TP53 mutations), and non-specific molecular profile (NSMP) lacking specific molecular features.

The researchers analyzed the survival benefits of combination immunotherapy strategies beyond standard platinum-based chemotherapy monotherapy in progressive and recurrent diseases. In particular, the addition of anti-PD-1 immune checkpoint inhibitors such as pembrolizumab or dostarlimab to standard chemotherapy with carboplatin and paclitaxel resulted in a dramatic increase in progression-free survival in patients with dMMR tumors.

The immunotherapy combination group recorded overwhelming clinical benefits, reducing the risk of disease progression and death by approximately 70% compared to the chemotherapy monotherapy group. In the pMMR patient group with intact mismatch repair function, combination therapy with immunotherapy also statistically significantly extended progression-free survival. Conversely, in the most aggressive p53 mutation subtype, a strategy precisely combining adjuvant cytotoxic chemotherapy with radiation therapy was identified as the key approach to reducing recurrence rates.

Implications and Outlook

This analysis, based on molecular pathological characteristics, demonstrates that endometrial cancer treatment has shifted from uniform stage-centered therapy to genomic precision medicine. Guidelines in the US and Europe have already begun recommending MMR protein immunohistochemistry and POLE gene analysis for all endometrial cancer patients at the time of initial diagnosis. This enables personalized prescriptions that avoid toxicity by reducing unnecessary adjuvant chemotherapy while administering immunotherapy early to high-risk groups.

The burden of treatment costs and the management of immune-mediated adverse events remain challenges to be addressed. Endocrine side effects and lung toxicity occurring during long-term immunotherapy administration require careful monitoring by clinicians. Furthermore, continuous work is needed to discover additional biomarkers to identify subgroups within the pMMR group that do not fully benefit from immunotherapy.

The early integration of combination immunotherapy in the treatment of patients with locally advanced and metastatic disease is rapidly changing clinical standards. As antibody-drug conjugates (ADCs) and molecular targeted therapies join as second-line treatment options, long-term survival rates for patients with refractory subtypes are also expected to improve further.

Endometrial cancer is the most common gynaecological cancer in high-income countries, the sixth most common cancer in women worldwide,1 and one of few cancers for which both the incidence and mortality rate are increasing.2,3 Although 75% of endometrial cancers present with early-stage disease when curable with surgery with or without adjuvant therapy, subsets of endometrial cancers with poor outcomes are increasing in incidence, more rapidly than cancers with better prognosis.4–6 Patients with advanced or recurrent disease are managed with platinum-based chemotherapy with or without immunotherapy, or hormonal therapy.

πŸ’¬Why it matters:

These research results provide the basis for fundamentally restructuring the clinical pathway for endometrial cancer, from primary care to tertiary hospitals. Through mandatory molecular subtype testing immediately after diagnosis, patients with POLE mutations, who have a very favorable prognosis, can avoid unnecessary radiation and adjuvant chemotherapy, thereby preventing overtreatment.

For patients with distant metastasis or local recurrence, a scenario has been established to prioritize first-line combination immunotherapy based on dMMR status to suppress disease progression early. The pharmaceutical and diagnostic industries have gained an opportunity to accelerate the development of multiplex gene panel diagnostic kits based on Next-Generation Sequencing (NGS) and to focus investment on developing next-generation targeted therapy pipelines to overcome immunotherapy resistance.

πŸ’¬ Comments

0 comments
Please log in to comment
Loading...

BioPlayground

Reading, linking, and lawful quotation stay open; high-speed bulk collection and unauthorized redistribution do not.

Unless stated otherwise, content rights belong to BioPlayground or the relevant rights holder.